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Abstract
Background: School-based mass treatment with praziquantel is the cornerstone for schistosomiasis control in school-aged
children. However, uptake of treatment among school-age children in Uganda is low in some areas. The objective of the
study was to examine the effectiveness of a pre-treatment snack on uptake of mass treatment.
Methods and Findings: In a cluster randomized trial carried out in Jinja district, Uganda, 12 primary schools were
randomized into two groups; one received education messages for schistosomiasis prevention for two months prior to mass
treatment, while the other, in addition to the education messages, received a pre-treatment snack shortly before mass
treatment. Four weeks after mass treatment, uptake of praziquantel was assessed among a random sample of 595 children
in the snack schools and 689 children in the non-snack schools as the primary outcome. The occurrence of side effects and
the prevalence and mean intensity of Schistosoma mansoni infection were determined as the secondary outcomes. Uptake
of praziquantel was higher in the snack schools, 93.9% (95% CI 91.7%–95.7%), compared to that in the non-snack schools,
78.7% (95% CI 75.4%–81.7%) (p= 0.002). The occurrence of side effects was lower in the snack schools, 34.4% (95% CI
31.5%–39.8%), compared to that in the non-snack schools, 46.9% (95% CI 42.2%–50.7%) (p= 0.041). Prevalence and mean
intensity of S. mansoni infection was lower in the snack schools, 1.3% (95% CI 0.6%–2.6%) and 38.3 eggs per gram of stool
(epg) (95% CI 21.8–67.2), compared to that in the non-snack schools, 14.1% (95% CI 11.6%–16.9%) (p= 0.001) and 78.4 epg
(95% CI 60.6–101.5) (p= 0.001), respectively.
Conclusions: Our results suggest that provision of a pre-treatment snack combined with education messages achieves a
higher uptake compared to the education messages alone. The use a pre-treatment snack was associated with reduced side
effects as well as decreased prevalence and intensity of S. mansoni infection.
Trial registration: http://www.ClinicalTrials.gov NCT01869465
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Introduction
Schistosomiasis is a major global public health problem
especially in sub-Saharan Africa [1–3]. The disability-adjusted
life-years (DALYs) loss attributable to schistosomiasis and soil
transmitted helminthiasis (STHs) combined (44 million) are more
than those due to malaria (36 million) and close to those due to
tuberculosis (47 million) [4–7]. According to the Global Burden of
Disease Study (2010), schistosomiasis alone is responsible for an
estimated 3.3 million DALYs [8].
Control strategies recommended by WHO for long-term
morbidity control of schistosomiasis include provision of safe and
effective anti-schistosomal drugs such as praziquantel, and
preventive measures focusing on health education, clean water,
and adequate sanitation [2,3,9–11]. In many developing countries
in sub-Saharan Africa including Burkina Faso, Ghana, Mali,
Niger, Ivory Coast, and Tanzania, regular chemotherapy with
praziquantel is implemented as the main strategy for schistosomi-
asis control with varying levels of success [11–13]. The target is to
provide regular treatment of at least 75% of school-age children at
risk of morbidity in order to keep the worm burden in individuals
low and confined [3]. In these countries, praziquantel is mainly
delivered through school-based health programs at low cost
[14–16].
In Uganda, school-based mass drug administration (MDA) for
schistosomiasis is the main approach that was adopted by the
national schistosomiasis control program and is currently imple-
mented in more than 38 districts within regions surrounding large
lakes and rivers [17]. The success of the school-based strategy was
based on the premise that schools are widely distributed
particularly in the rural areas with high enrollment and attendance
rates, that teachers are willing to administer the drugs to the
children, and that the children will accept the treatment. The
benefit of this approach has been documented [18–20]. However,
studies undertaken among school children have reported low
uptake of praziquantel [21–23]. The fear of treatment and low
school-attendance rates were highlighted as some of the major
contributors to the low uptake. Praziquantel is generally perceived
to be a strong drug that causes transient sickness and occasional
fatalities and resistance to take the drug has been reported [24–
27]. In a particular study conducted in Jinja district in Uganda, the
fear of side effects of praziquantel, lack of knowledge about
schistosomiasis prevention, and lack of teacher support to
distribute treatment were the major factors thought to underpin
the low uptake [23].
Due to the risk of side effects and the difficulties of administering
a large number of tablets to individuals, drug administration
should be accompanied by precautionary measures before mass
treatment is rolled out [28]. The administration of praziquantel
should be accompanied by concomitant administration of food to
reduce the risk of side effects of the drug [29–31]. Considerable
reductions in occurrence of side effects and high treatment
coverage have been reported by large-scale national control
programs where special feeding programs for the children to
mitigate the side effects were provided [31,32]. The Ugandan
Government’s policy under the universal primary education
program requires that parents and care takers of children take
responsibility for feeding their children while at school [33,34]. In
many parts of the country, children go to school in the morning
without a meal because many parents cannot afford to meet the
cost of a daily meal for their children while at school [34]. This
situation implies that in schools where annual mass treatment for
schistosomiasis is implemented, most children take the treatment
on empty stomachs with the risk of widespread side effects
[23,35,36]. In this study, we hypothesized that provision of a pre-
treatment snack in combination with education messages for
schistosomiasis prevention would improve uptake as well as reduce
the occurrence of side effects attributable to praziquantel. It was
anticipated that the improved uptake would reduce the prevalence
and intensity of schistosomiasis infection.
Materials and Methods
Ethical Considerations
The study protocol was approved by Makerere University
College of Health Sciences Higher Degrees, Research and
Ethics Committee and granted ethical clearance by the Uganda
National Council for Science and Technology. One month prior
to the study, the objectives and the procedures of the study were
explained to the district health and education authorities and to
the parents or guardians of all children in the schools through
half-day meetings held at the district health headquarters and
the respective schools. During the meetings held in schools,
written informed consent was obtained from the parents or
guardians of all the children. Assent to participate in the study
was obtained from all children. Children identified with
schistosomiasis and/or STH were treated with praziquantel
and/or albendazole.
Study Setting
The study was carried out in 12 primary schools in Walukuba
division, Jinja district of south eastern Uganda between May
and July 2013. Intestinal schistosomiasis is highly endemic in the
area. School-based mass treatment for schistosomiasis is
implemented in the division on an annual basis as a standalone
intervention. In 2013, mass treatment was conducted in June.
Prior to mass treatment, the Vector Control Division of the
Ministry of Health conducted refresher training for members of
the district health team and the district education office. The
district then cascaded training and supervision duties to the sub-
county health assistants and inspector of schools who in turn,
trained and supervised the school teachers. In addition,
awareness of schistosomiasis control was communicated through
radio talk shows and radio spot messages. The drugs, tally sheets
and registers were distributed to the primary schools after the
training. During mass treatment, a central location in each
school was organized for drug administration. Children were
invited according to their grade, to receive treatment. Prazi-
quantel was distributed according to the height of the child
using a standard dose pole, which provides a simple and
reasonably accurate estimate of weight [37]. These activities
were supported through a parallel structure within the Ministry
of Health with external funding from the United States Agency
for International Development (USAID) channelled through
Research Triangle Institute (RTI) International.
Study Design, Stratification, and Randomization
This was a cluster randomized trial during which 12 primary
schools were grouped into two strata of six schools each according
to the 2012 uptake levels of praziquantel; low (,55%) uptake and
high ($55%) uptake [38]. From each stratum, the schools (clusters)
were randomized into two groups of six schools each; the snack
and the non-snack group using a computer generated program in
STATA 10.0 (Figure 1). A cluster design was adopted for logistical
convenience since the study evaluates unblinded interventions that
would otherwise cause resentment or contamination if they were
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to be provided for some children but not others in the same
schools. Stratification was aimed at creating a good balance in
participant characteristics in terms of uptake levels of praziquantel
in each group (Figure 1). Randomization was performed by an
independent statistician.
The Interventions
This included a pre-treatment snack. In addition, education
messages for schistosomiasis prevention were provided.
The pre-treatment snack. The snack consisted of mango
juice and doughnuts. These were considered safe for consumption,
Figure 1. Study profile showing stratification and randomization of the schools to the intervention groups and the selection of
children for assessment after mass treatment.
doi:10.1371/journal.pmed.1001640.g001
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were locally available at low cost, could be easily transported to the
schools, stored, and distributed to the children during mass
treatment. Each child in the snack schools received 500 ml of
mango juice and a doughnut shortly before swallowing prazi-
quantel during mass treatment. A total of 2,833 children in six
primary schools received the snack. Ingredients of the mango juice
included vitamin C, fruit flavors from concentrate, sugar, water,
citric acid, color E 110, and preservative E 221. The 500 ml
bottles of mango juice are certified by the Uganda national bureau
of standards and were considered safe for human consumption.
The doughnuts were made of wheat flour, baking powder, sugar,
and cooking oil. A local manufacturer was contracted to make,
pre-pack, and distribute the snack to the schools. The snack was
distributed by the class teachers who also distributed and recorded
the treatment in separate registers.
The education messages. In addition to the pre-treatment
snack, education messages for schistosomiasis prevention were
provided. These were developed by the authors in collaboration
with the district health and education sectors. The messages were
tailored to the knowledge gap established earlier [23] and included
the following aspects: (i) dangers of schistosomiasis infection; (ii)
acquisition of infection from contaminated water; (iii) prevention
of acquiring the infection by avoiding unnecessary water contact;
(iv) taking preventive treatment (praziquantel) annually to avoid
getting serious disease; (v) taking the treatment with food in order
to avoid the side effects of the drugs. The head teachers and school
teachers in charge of health and sanitation were trained in the
above aspects of schistosomiasis prevention through a two-day
workshop, during which the print materials of the messages were
also distributed. School children in both the snack and the non-
snack group received a 30-minute session of the above messages,
twice a week for two months, prior to mass treatment. A total of
5,920 children in the 12 primary schools received the messages.
The trained teachers delivered the messages in both the local
language of Lusoga and English through face to face interactions
with the children during school assemblies.
Costs. The total cost of providing the pre-treatment snack
and education messages was estimated at US$0.6 and US$0.1 per
child, respectively.
Sample Size
The sample size used in this study was based on that required to
detect an increase in uptake from 49% registered in 2012 [38] to
the recommended 75% [3]. At 90% power and a 95% CI, the
sample size required to detect this difference was 79 in the snack
schools and 79 in the non-snack schools (STATA 10.0). This
sample size was adjusted by 10% non-response to 87. Because of
the cluster design, a design effect of 6.3 from a previous study [23]
was applied to obtain a minimum sample size of 548 in the snack
schools and 548 in the non-snack schools.
Sampling, Eligibility Criteria, and Data Collection
Sampling and data collection were conducted one month after
mass drug administration. The study schools were pre-visited to
obtain updated school populations. Probability proportion to size
of the school and grade populations was used to determine the
number of children selected from each school and grade in the two
groups. Children were randomly selected from grades 4–6 using
systematic sampling. Children were considered eligible for the
study if they had been enrolled or attended class at the school for
more than six months prior to data collection and were present at
school during mass treatment. Experienced research assistants, all
blinded to the children’s intervention groups conducted face to face
interviews with each selected child using structured questionnaires.
Throughout data collection, the research assistants were not
made aware of the intervention groups. Stool specimens from
each child were concurrently collected, processed, and examined
for S. mansoni infection. Children who failed to provide stool
specimens for examination were replaced by randomly selecting
an equal number of children from grades 4–6. A total of 12
children did not provide stool specimens and were replaced.
Throughout the stool collection procedure, boys and girls were
separated. The data were made available and shared with the
national Vector Control Division, Ministry of Health.
Measures
Measures were determined at both the cluster and individual
levels. The primary outcome was uptake of mass treatment. The
secondary outcomes were occurrence of side effects, knowledge of
schistosomiasis prevention, and prevalence and intensity of S.
mansoni infection in the two groups. In addition, the socio-
demographic characteristics of the children were also assessed.
The proportion of children who received education messages and
a snack prior to mass treatment in the two groups was calculated.
Uptake of praziquantel was defined as having received and
swallowed the drug during mass treatment, which was measured
through self-report. Children who reported to have swallowed
treatment were asked if they developed any side effects after
swallowing the drug. The socio-demographic characteristics
assessed included age, sex, school name, grade (year), and distance
of residence/school from the lake. Knowledge of schistosomiasis
prevention was measured on a score scale of 1–3. The children
were asked the different ways through which the infection can be
transmitted and prevented, including taking preventive treatment.
For each of the correct responses, a score of 1 was awarded.
Children who mentioned at least one correct method of
transmission and two correct methods of prevention scored an
aggregate of 3 and were regarded as having correct knowledge of
schistosomiasis prevention.
Stool examination for diagnosis of S. mansoni
infection. On two consecutive days, early morning stool
specimens were collected from each child. From each specimen,
two slides were prepared using the modified Kato-Katz thick
smear technique [39] with a 41.7 mg template. Two experienced
technicians, all blinded to the children’s intervention groups,
examined the slides under the microscope (106). An independent
technician read a random 10% of stool slides and the results were
compared. If there was a discrepancy of more than 5%, the slides
were read again by two independent technicians until counts
harmonized. However, all results concurred with those of the third
technician. The egg counts were found to be over dispersed and
thus were logarithmically transformed and intensities reported as
geometric mean intensity (GMI) of eggs per gram of stool (epg)
among positives only. In case of the presence of soil transmitted
helminthiasis (STH) infections on the slides, this was registered so
the child could be treated.
Data Management and Statistical Analysis
Double data entry and validation was performed in EpiInfo
software (version 7.1.2; Centers for Disease Control and Preven-
tion, Atlanta (Georgia), US). After internal consistency checks, the
cleaned dataset was exported to STATA 10.0 for analysis. To
determine whether the groups were comparable in terms of uptake
and prevalence and intensity of S. mansoni infection, the uptake
levels and prevalence and intensity of S. mansoni infection in a
random sample of another set of children in the same schools
during a previous mass treatment of 2012 were compared.
However, since the children were selected at random in both
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studies, it is possible that some of the children examined in 2012
could have been re-examined in 2013. Differences in the
demographic and descriptive variables between the groups were
compared using chi squared tests for dichotomized or categorical
variables. Student’s t-test was used to compare mean intensity of S.
mansoni infection. To adjust for clustering, comparisons with test
statistics based on chi squared tests were divided by the design
effect, while test statistics based on the t-test were divided by the
square root of the design effect [40,41]. To evaluate the effect of
the snack on uptake, a logistic regression mixed effects model
allowing for fixed (school-level) and participant-level random
effects was applied. ANOVA was used to compare the effect of the
snack on mean intensity infection with regard to sex and age. All
the analyses were planned prior to the study.
Quality Control
Experienced research assistants who were fluent in the local
language of Lusoga were recruited and trained in data collection
methods. The questionnaires were translated into Lusoga and then
back translated to ensure consistency in meaning. They were then
pre-tested in one of the schools in a non-study area for purposes of
clarity, validation, suitability, and logical flow of the questions.
Interviews with the children were held in a private and quiet
environment within the school premises. Data were checked for
completeness and accuracy before leaving the field and conse-
quently, no data were missing. The first author closely supervised
the research assistants during data collection.
Results
Baseline Characteristics
A total of 1,284 children in 12 primary schools were assessed:
595 (46.3%) in the snack schools and 689 (53.7%) in the non-snack
schools. The mean age was 11.3 years (standard deviation [SD]
1.7) and 11.7 years (SD 1.6) in the snack and non-snack schools,
respectively. The majority 317 (53.3%) in the snack schools and
365 (53.0%) in the non-snack schools were aged between 12 and
16 years. Children in both groups were comparable in terms of age
group, sex, distance from area of residence to the lake, and
knowledge of schistosomiasis prevention (p.0.05) (Table 1). The
uptake levels and prevalence and intensity of S. mansoni infection in
a random sample of children in the same schools during a previous
mass treatment of 2012 were also comparable. Uptake of
praziquantel in the snack schools was 46.5% while that in the
non-snack schools was 51.0% (p=0.57). The prevalence of S.
mansoni infection in snack schools was 34.4% compared to 30.9%
Table 1. Baseline characteristics of the two intervention groups.
Characteristic Non-snack Schools (n=689) (%) Snack Schools (n=595) (%) x2a p-Value
Age group
7–11 years 291 (42.2) 310 (52.1) 1.981 0.16
12–16 years 398 (57.8) 285 (47.9) — —
Sex
Female 343 (49.8) 296 (49.8) 0.00003 0.99
Male 346 (50.2) 299 (50.3) — —
Distance from area of residence to the lake
#5 km 330 (47.9) 284 (47.7) 0.0035 0.98
.5 km 359 (52.1) 311 (52.3) — —
Knowledge of schistosomiasis prevention
Yes 595 (86.4) 500 (84.0) 0.2179 0.64
No 94 (13.6) 95 (16.0) — —
aAdjusted for cluster design effect.
doi:10.1371/journal.pmed.1001640.t001
Table 2. Uptake of praziquantel, prevalence, and intensity of S. mansoni infection among a random sample of
children in the same schools during the 2012 mass treatment.
Characteristic Non-snack Schools (n=543) (%) Snack Schools (n=477) (%) Test Statistica p-Value
Self-reported uptake of praziquantel
Yes 277 (51.0) 222 (46.5) x2 = 0.322 0.57
No 266 (48.9) 255 (53.5) — —
S. mansoni infection status (%)
Positive 168 (30.9) 164 (34.4) x2 = 0.217 0.64
Negative 375 (69.1) 313 (65.6) — —
Intensity of S. mansoni infection (epg)
GMI epg 120.5 115.9 t=21.126 0.26
aAdjusted for cluster design effect.
doi:10.1371/journal.pmed.1001640.t002
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Table 3. Characteristics of the snack and non-snack schools after the interventions.
Variable
Non-snack Schools
n=689 (%)
Snack Schools
n=595 (%) Test Statistica p-Value
Received education messages prior to mass
treatment (%)
Yes 492 (71.4) 436(73.3) x2 = 0.089 0.77
No 197 (28.6) 159 (26.7) — —
Eaten something prior to mass treatment (%)
Yes 270 (49.8) 519 (92.8) x2 = 39.825 ,0.001
No 272 (50.2) 40 (7.2) — —
Type of food/snack taken prior to mass
treatment (%)
Mango juice and doughnut 14 (5.2) 481 (92.7) x2 = 95.333 ,0.001
Maize porridge 130 (48.2) 2 (0.4) — —
Posho and beans 18 (6.7) 12 (2.3) — —
Other (pancakes, bananas, cassava, bread, and dry tea) 108 (40.0) 24 (2.3) — —
Self-reported uptake of praziquantel (%)
Yes 542 (78.7) 559 (93.9) x2 = 9.683 0.002
No 147 (21.3) 36 (6.1) — —
Side effects attributable to praziquantel (%)
Yes 254 (46.9) 192 (34.4) x2 = 4.181 0.041
No 288 (53.1) 367 (63.6) — —
Reported side effects attributable to
praziquantel (%)
Abdominal pain 133 (52.4) 109 (56.8) x2 = 0.738 0.947
Dizziness 61 (24.0) 45 (23.4) — —
Diarrhea 31 (12.2) 27 (14.1) — —
Vomiting 19 (7.5) 7 (3.6) — —
Other (headache, nausea) 10 (3.9) 4 (2.1) — —
S. mansoni infection status (%)
Positive 97 (14.1) 8 (1.3) x2 = 10.937 0.001
Negative 592 (85.9) 587 (98.7) — —
Intensity of S. mansoni infection (epg)
GMI epg 78.4 38.3 t= 18.54 0.001
aAdjusted for cluster design effect.
doi:10.1371/journal.pmed.1001640.t003
Table 4. Estimated crude odds ratios and adjusted odds ratio and their 95% CI from the final logistic regression
mixed-effects model.
Variable COR (95% CI) p-Value AOR (95% CI) p-Value
Distance from area of residence to the lake
#5 km 1.59 (1.08–2.38) 0.022 1.00 (0.59–1.70) 0.99
Going to the lake
Yes 1.59 (1.07–2.38) 0.022 1.52 (0.87–2.68) 0.14
Correct knowledge of schistosomiasis prevention
Yes 4.44 (3.01–6.54) ,0.001 1.39 (0.68–2.94) 0.39
Sensitized about schistosomiasis prevention
Yes 12.2 (7.99–18.60) ,0.001 13.1 (8.29–20.80) ,0.001
Intervention
Snack group 4.19 (2.67–6.59) ,0.001 4.61 (2.48–8.58) ,0.001
Adjusted for age and sex.
COR, crude odds ratio.
doi:10.1371/journal.pmed.1001640.t004
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in the non-snack schools (p=0.64) and the intensity of S. mansoni
infection was 115.9 epg and 120.5 epg in the snack and non-snack
schools (p=0.26), respectively (Table 2) [38].
Proportion of children who received education messages
and a pre-treatment snack. The majority of children in the
snack 436 (73.3%) and non-snack schools 492 (71.4%) reported to
have received education messages for schistosomiasis prevention
prior to mass treatment (p=0.766). A total of 519 (92.8%) and
270 (49.8%) children in the snack and non-snack schools,
respectively, reported to have eaten something prior to mass
treatment (p,0.001). The majority (92.7%) in the snack received
mango juice and doughnuts while 48.2% in the non-snack schools
reported to have taken maize porridge, 6.7% reported posho and
beans, 5.2% mango juice and doughnut, and 40.0% reported
other types of food including pancakes, bananas, cassava, bread,
and dry tea.
Primary Outcome
Self-reported uptake of praziquantel. Uptake of prazi-
quantel in the snack and non-snack schools was 93.9% and 78.7%,
respectively (p=0.002).
Secondary Outcomes
Occurrence of side effects and prevalence and intensity of
S. mansoni infection. The children who reported to have
developed side effects in the snack and non-snack schools were
comparable in terms of age (p=0.08) and sex (p=0.55). The
proportion of children who reported to have developed at least one
side effect after swallowing praziquantel was 34.4% in the snack
schools compared to 46.9% in the non-snack schools (p=0.041).
The occurrence of side effects among the infected children was 34
(7.6%) and that among the non-infected was 421 (92.4%)
(p=0.016). The most common reported side effects in both
groups included abdominal pain, dizziness, diarrhea, and vomit-
ing. Among the children who reported to have eaten something
prior to mass treatment, 276 (36.3%) developed side effects
compared to 163 (53.4%) among the children who did not eat
anything (p,0.001).
The difference in prevalence of S. mansoni infection between the
two groups was statistically significant (p=0.001). The prevalence
and GMI of S. mansoni infection was 1.3% and 38.3 epg and
14.1% and 78.4 epg in the snack and non-snack schools,
respectively (Table 3). Children who reported to have taken
praziquantel had a lower prevalence of infection, 60/1,101 (5.5%),
compared to those who did not take praziquantel, 45/183 (24.6%)
(prevalence ratio = 1.83 [95% CI 1.60–2.10], p,0.001). Similarly,
the GMI of infection was lower among children who reported to
have taken praziquantel, 46.2 epg (95% CI 35.0–60.9) compared
to those who reported not to have taken the drug, 106.1 epg (95%
CI 74.7–150.6).
Exploratory Outcomes
Through a step-wise forward selection method, covariates
with p,0.2 from the unadjusted model (distance from area of
residence to the lake, going to the lake, having received
education messages prior to mass treatment, knowledge of
schistosomiasis prevention, and intervention group) were con-
sidered for inclusion in the multivariable adjusted model. The
covariates retained in the final model were belonging to the
snack group (adjusted odds ratio [AOR] 4.61, 95% CI 2.48–
8.58, p,0.001) and having received education messages prior to
mass treatment (AOR 13.3, 95% CI 8.29–20.80, p,0.001)
(Table 4).
Discussion
This study found that provision of a pre-treatment snack to
school children increases uptake of mass treatment for schistoso-
miasis. The use of a pre-treatment snack is associated with reduced
side effects attributable to praziquantel. The increased uptake in
the snack group is associated with reduced prevalence and
intensity of schistosomiasis infection among school children.
The self-reported uptake of praziquantel by children in the
snack schools (93.9%) was considerably higher than in the non-
snack schools (78.7%). A comparable high coverage (94.0%)
among school children was achieved by the national control
program in Sierra Leone where a special feeding program for the
children was provided [32]. We ascribe the observed difference in
uptake between the two groups to the pre-treatment snack. The
provision of food is an incentive for children to participate in
school activities including health intervention programs [42,43].
The fact that praziquantel should be taken with food to mitigate
the side effects was well known by the children because it was part
of the education messages given to the children prior to mass
treatment. In a previous mass treatment, more than two-thirds of
the children reported fear of side effects as the major reason for
non uptake of praziquantel [23]. In this study, more than half of
the children in the non-snack schools did not take anything prior
to mass treatment while the majority (92.8%) in the snack group
received a snack before swallowing the drug. Thus, provision of a
snack to mitigate the side effects of praziquantel could have
motivated the children to take treatment.
Praziquantel is the current drug of choice for schistosomiasis
control and is virtually the only anti-schistosomal drug readily
available for treatment [28,44,45]. The drug is given orally, is
effective as a single dose for the three major species of
schistosomes, has a low toxicological profile, is well tolerated,
and confers some resistance to re-infection [46]. However,
praziquantel causes transient side effects of the gastro-intestinal
and central nervous systems especially when the drug is taken on
an empty stomach. Food high in carbohydrate content increases
absorption of the drug from the gastro-intestinal tract, enhances its
bioavailability, and lowers the odds of side effects [29–31].
Praziquantel undergoes first-pass metabolism through the cyto-
chrome P450 pathway and only small amounts reach circulation.
In the presence of high carbohydrate food, hydroxylation of the
drug is inhibited and the renal clearance reduced, leading to
increased plasma levels [29,30]. By disrupting calcium ions’ (Ca2+)
homeostasis, praziquantel increases the permeability of the
schistosome membranes to Ca2+ and the resultant rapid influx
of Ca2+ causes paralysis of the parasites in a contracted state. The
side effects experienced after taking the drug are a result of the
contents released by the dead parasites and the subsequent host
immune reaction. The frequency and severity of the side effects
increase with increasing parasite burden [47]. In this study, the
occurrence of side effects among the infected children was lower
(7.6%) than among the non-infected children (92.4%). The
observed difference could be attributable to the effect of the
snack. Besides, the prevalence of S. mansoni infection among the
children who took praziquantel was generally very low (5.6%).
The major side effects reported after mass treatment in this study
included abdominal pain, dizziness, diarrhea, and vomiting.
Similar side effects have been reported in other studies [32,47–
49]. The lower occurrence of the side effects in the snack schools
(34.4%) compared to the non-snack schools (46.9%) is probably
attributable to the pre-treatment snack. However, even in the
presence of a snack, more than a third of the children in the snack
group reported to have experienced the side effects. A comparable
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proportion of children experiencing similar side effects after taking
praziquantel with a snack was reported in Ghana (28%), Tanzania
(31%) [48], and in Sierra Leon (30%) [50]. The probable
explanation for the occurrence of side effects even when the drug
is taken with food is the presence of moderate intensity of
schistosomiasis infection among the children before treatment.
Because the prevalence and intensity of infection in the snack and
non-snack arm were comparable during the 2012 post mass
treatment, the difference in the frequency of side effects between
the two groups cannot be attributed to the difference in prevalence
and intensity of infection with schistosomiasis.
The efficacy of praziquantel against adult schistosomes is
indisputable [20,51–53], and the reduction in prevalence and
intensity of schistosomiasis infection depends on achieving and
maintaining high treatment coverage [3,28]. The lower prevalence
and intensity of S. mansoni infection in the snack schools compared
to the non-snack schools is probably due to the higher uptake of
praziquantel in the snack schools compared to that in the non-
snack schools.
Study Limitations
The study assessed uptake of praziquantel and side effects of the
drug based on self-report. It is possible that children could have
provided socially desirable answers. However, measures were
undertaken to ensure fairly accurate self-report on uptake and side
effects. First, the study was conducted four weeks after mass
treatment, a period short enough to minimize recall bias.
Secondly, the questionnaires used were pre-tested in one of the
schools in a non-study area and none of the children interviewed
failed to recall whether they had received treatment or not at the
last mass distribution. Children were able to recall treatment
because praziquantel tablets are unusually large, pungent, and
unpalatable. Similar methods for measuring uptake of treatment
have been successfully used in northern and south-eastern regions
of Uganda [54]. Thirdly, a number of relationships corroborated
evidence that self-report in our study is fairly accurate. For
instance, among the children who reported uptake of praziquantel,
more than 95% were able to recall and mention the true color of
praziquantel and more than 96% were able to recall whether they
experienced side effects with the drug or not. Lastly, the
comparison of the self-reported uptake with the S. mansoni infection
status and intensity validated the self-reported uptake as accurate.
The prevalence of S. mansoni infections was lower in children who
reported to have taken the drug compared to those who did not
take the drug. Besides, the proportion of socially desirable answers
was expected to be similar in both groups and should therefore
have no effect on the direction of the conclusions regarding
prevalence and intensity of infection attributable to the snack.
Another limitation is the cost of the snack used in the study. It is
not known whether alternative food such as maize porridge would
be as effective as the doughnuts and mango juice and may need
further testing.
Conclusion
This study shows that provision of a pre-treatment snack can
improve uptake of mass treatment as well as reduce the side effects
attributable to praziquantel treatment. The increased uptake
significantly reduces the prevalence and intensity of S. mansoni
infection in this age group. A detailed cost-effectiveness analysis of
provision of locally available and relatively low cost food with
comparable efficacy, such as maize porridge, during mass
treatment for schistosomiasis should be undertaken and if found
cost-effective, provision of food should be integrated into school-
based mass treatment. This strategy may be applicable at the
national level and other similar settings in sub-Saharan Africa to
increase treatment coverage among school children.
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Editors’ Summary
Background. Globally, more than 240 million people are
infected with schistosomes, a parasitic worm found in
tropical and sub-tropical fresh water. Schistosomes repro-
duce in snails, which release free-swimming infectious
parasites that burrow into the skin of people when they
wash or swim in contaminated water. Once inside a person,
the parasites turn into larvae and migrate to the liver, where
they become juvenile worms. These mature into 10–20 mm
long adult worms and take up residence in the veins draining
the gut or bladder where they mate and release eggs, some
of which pass into the feces and go back into water where
they hatch and infect fresh snails. Most people have no
symptoms when they are first infected with schistosomes
but some develop a rash or itchy skin. Later symptoms
include fever, chills, cough, and muscle aches. Without
treatment, schistosomiasis can persist for years, eventually
causing liver, gut, bladder, and spleen damage. In Africa
alone, schistosomiasis kills about 280,000 people annually.
Why Was This Study Done? Strategies for the control of
schistosomiasis include the provision of clean water and
adequate sanitation, and education. However, the corner-
stone of control is the reduction of disease through periodic,
targeted treatment with the anti-schistosomal drug prazi-
quantel. One group that is targeted for treatment in
countries affected by schistosomiasis is school-aged children.
For this approach to be successful, experts recommend
regular treatment of at least 75% of school-age children at
risk of infection. Unfortunately, the uptake of the interven-
tion is often low, partly because children fear praziquantel’s
side effects, which include diarrhea, and vomiting. The risk of
developing side effects can be reduced by eating food just
before taking the drug. In this cluster randomized trial (a
study that compares outcomes in groups of people
randomly assigned to receive different treatments), the
researchers investigate whether the provision of a pre-
treatment snack improves the uptake of praziquantel among
school children in Jinja district of Uganda, a country that has
adopted school-based mass drug administration as part of its
national schistosomiasis control program. The researchers
also investigated whether this intervention reduces the
occurrence of side effects attributable to praziquantel, the
prevalence of schistosomiasis (the proportion of the popu-
lation that is infected), and the infection intensity (indicated
by the density of eggs in stool).
What Did the Researchers Do and Find? The researchers
randomly assigned 12 primary schools to receive education
messages for 2 months before mass treatment with
praziquantel or the same education messages plus a mango
juice and donut snack just before treatment. The education
messages included information about the dangers of
schistosome infection, the importance of preventative
treatment with praziquantel, and information about taking
the drug with food to avoid side effects. Four weeks after
mass treatment, praziquantel uptake was assessed by self
report in 595 children chosen randomly from the snack
schools and 689 children from the no-snack schools. Uptake
of praziquantel in the snack and no-snack schools was 93.9%
and 78.7%, respectively, a significant difference in outcomes
that is unlikely to be a chance event. The occurrence of self-
reported side effects, the prevalence of schistosome infec-
tion, and the average intensity of infection were all
significantly lower in the snack schools than in the no-snack
schools.
What Do These Findings Mean? These findings suggest
that the provision of a pre-treatment snack combined
with education messages improved uptake of mass
treatment for schistosomiasis among school children in
Uganda compared to education messages alone. The
intervention also reduced the occurrence of side effects,
the prevalence of infection, and the infection intensity.
Because uptake and the occurrence of side effects were
determined by self-report, some children may have
provided socially desirable answers. That is, they may
have said they took the drug when they didn’t because
they knew that is what the researchers wanted to hear.
However, the infection prevalence and intensity findings
validate the self-reported uptake. The researchers con-
clude that the provision of a snack to mitigate the side
effects of praziquantel could have motivated the
children to take the treatment. If future trials show that
the intervention is cost-effective, the researchers sug-
gest that the provision of pre-treatment food should be
integrated into school-based mass treatment programs
for schistosomiasis control at the national level in
Uganda and in similar settings elsewhere in sub-Saharan
Africa.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001640.
N The World Health Organization provides detailed informa-
tion about schistosomiasis (in several languages)
N The US Centers for Disease Control and Prevention
provides information for the public and for health
professionals about all aspects of schistosomiasis (in
English and Spanish)
N The UK National Health Service Choices website also
provides information about schistosomiasis
N More information about the Evaluation of Strategies for
Improved Uptake of Preventive Treatment for Intestinal
Schistosomiasis trial is available
N The End Fund, a US not-for-profit organization that aims
to tackle schistosomiasis and other neglected tropical
diseases, has a personal story about dealing with
schistosomiasis
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